These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 16317590

  • 1. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL, Lladó Plarrumaní A.
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [Abstract] [Full Text] [Related]

  • 2. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A, Alfaro V.
    Rev Neurol; 2005 Dec; 42(10):607-16. PubMed ID: 16703529
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [The clinical relevance of memantine use].
    Sobów T.
    Psychiatr Pol; 2004 Dec; 38(2):321-30. PubMed ID: 15307296
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS, Lipton SA.
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [Abstract] [Full Text] [Related]

  • 12. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I.
    Dement Geriatr Cogn Disord; 2007 Jun; 23(5):301-6. PubMed ID: 17356273
    [Abstract] [Full Text] [Related]

  • 13. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL.
    J Clin Psychiatry; 2006 Jun; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H, Grossberg GT.
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [Abstract] [Full Text] [Related]

  • 16. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
    Danysz W, Parsons CG.
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
    [Abstract] [Full Text] [Related]

  • 17. [Therapy of Alzheimer disease].
    Kovács T.
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [Abstract] [Full Text] [Related]

  • 18. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
    Grossberg GT, Pejović V, Miller ML, Graham SM.
    Dement Geriatr Cogn Disord; 2009 Mar; 27(2):164-72. PubMed ID: 19194105
    [Abstract] [Full Text] [Related]

  • 19. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis.
    Livingston G, Katona C.
    Int J Geriatr Psychiatry; 2004 Oct; 19(10):919-25. PubMed ID: 15449303
    [Abstract] [Full Text] [Related]

  • 20. [The action of memantine on the cognitive disorders of patients with dementia: reflections following two years' experience in Spain].
    Robles-Bayón A.
    Rev Neurol; 2004 Oct; 42(5):288-96. PubMed ID: 16538592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.